

Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.
You can purchase shares of Glaukos (NYSE:GKOS) through any online brokerage.
Other companies in Glaukos’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
Glaukos has a consensus price target of $165.75.
The stock price for Glaukos (NYSE: GKOS) is $178.5 last updated October 27, 2026 at 9:30 AM EDT.
There are no upcoming dividends for Glaukos.
Glaukos does not have any upcoming earnings scheduled.
There is no upcoming split for Glaukos.
Glaukos is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has...